Peptide reference
Carnosine
L-Carnosine ·β-Alanyl-L-histidine ·Beta-alanyl-L-histidine ·Karnosin
What cited sources report about carnosine
Carnosine (β-alanyl-L-histidine) is an endogenous dipeptide concentrated in skeletal muscle, brain, and other excitable tissues, biosynthesized from beta-alanine and histidine by carnosine synthase. It is widely available as a dietary supplement (oral L-carnosine) and as the lubricant-eyedrop ingredient N-acetylcarnosine. There is no FDA-approved drug indication for carnosine in the cited sources, and no PCAC nomination is on the public docket. The summaries below report what individual cited sources state; this page does not assert claims beyond what those sources report.
Boldyrev et al. (2013) — Physiological Reviews
A comprehensive review by Boldyrev (Lomonosov Moscow State University), Aldini (University of Milan), and Derave (Ghent University) characterized carnosine biochemistry across pH-buffering, metal-chelation, antioxidant, and antiglycation roles, and surveyed preclinical and clinical literature across diabetes, ocular disease, aging, and neurological disorders. The authors observed that the therapeutic potential of carnosine has been examined in conditions involving ischemic or oxidative stress and characterized clinical results to date as preliminary.
The therapeutic potential of carnosine supplementation has been tested in numerous diseases in which ischemic or oxidative stress are involved.
Cesak et al. (2023) — Nutrients
A narrative review of human-medicine evidence for carnosine, N-acetylcarnosine, and zinc-L-carnosine catalogued indications with reported beneficial signals (sarcopenia, cognitive aging, neurodegeneration, diabetes parameters, oral mucositis, gastrointestinal protection in H. pylori contexts) and indications with inconclusive evidence (senile cataracts, cardiovascular disease, schizophrenia, autism spectrum disorder). The authors observed that most trials were small and that confirmatory phase-3 evidence was lacking for any individual indication.
Evidence showed that the supplementation had a beneficial impact in the prevention of sarcopenia, the preservation of cognitive abilities and the improvement of neurodegenerative disorders.
Saunders et al. (2017) — British Journal of Sports Medicine
A systematic review and meta-analysis of beta-alanine supplementation — the rate-limiting precursor for endogenous carnosine biosynthesis — pooled 40 individual studies and over 1,400 participants. The authors reported a small but statistically significant ergogenic effect on exercise capacity in tasks of approximately 30 seconds to 10 minutes duration, with the largest effect sizes observed in shorter, high-intensity protocols.
PubChem CID 439224 — National Center for Biotechnology Information
The PubChem compound record for L-carnosine lists molecular formula C9H14N4O3, consistent with the dipeptide β-alanyl-L-histidine. The record aggregates synonyms — including karnosin and ignotin — and links to the underlying chemical and biochemical literature.
Coverage notes
Carnosine is endogenous and is regulated in the US as a dietary-supplement ingredient under DSHEA, not as a drug. The cited literature is dominated by preclinical mechanism studies and small clinical trials in heterogeneous indications; the Cesak 2023 review explicitly notes that confirmatory phase-3 evidence is lacking for any individual indication. Beta-alanine, the rate-limiting biosynthetic precursor, has a substantially larger ergogenic-supplementation evidence base than carnosine itself; Saunders 2017 is included here because beta-alanine supplementation acts by raising endogenous muscle carnosine. N-acetylcarnosine eyedrops (sold for cataract use in some non-US markets) lie outside the cited sources for this page.